[go: up one dir, main page]

PT3692983T - Formulações orais de análogos da citidina e métodos de utilização dos mesmos - Google Patents

Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Info

Publication number
PT3692983T
PT3692983T PT192131480T PT19213148T PT3692983T PT 3692983 T PT3692983 T PT 3692983T PT 192131480 T PT192131480 T PT 192131480T PT 19213148 T PT19213148 T PT 19213148T PT 3692983 T PT3692983 T PT 3692983T
Authority
PT
Portugal
Prior art keywords
methods
oral formulations
cytidine analogs
cytidine
analogs
Prior art date
Application number
PT192131480T
Other languages
English (en)
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40941609&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3692983(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of PT3692983T publication Critical patent/PT3692983T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT192131480T 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos PT3692983T (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US5360908P 2008-05-15 2008-05-15
US20114508P 2008-12-05 2008-12-05
US15787509P 2009-03-05 2009-03-05

Publications (1)

Publication Number Publication Date
PT3692983T true PT3692983T (pt) 2021-11-08

Family

ID=40941609

Family Applications (5)

Application Number Title Priority Date Filing Date
PT202011433T PT3782612T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT09746975T PT2299984T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos da sua utilização
PT202011052T PT3782611T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT192131480T PT3692983T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT131827214T PT2695609T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Family Applications Before (3)

Application Number Title Priority Date Filing Date
PT202011433T PT3782612T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos
PT09746975T PT2299984T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos da sua utilização
PT202011052T PT3782611T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT131827214T PT2695609T (pt) 2008-05-15 2009-05-14 Formulações orais de análogos da citidina e métodos de utilização dos mesmos

Country Status (34)

Country Link
US (12) US8846628B2 (pt)
EP (6) EP3782611B1 (pt)
JP (3) JP2011520880A (pt)
KR (1) KR101633134B1 (pt)
CN (3) CN102099018B (pt)
AR (1) AR071808A1 (pt)
AU (3) AU2009246926B2 (pt)
BR (1) BRPI0912717A2 (pt)
CA (3) CA3094590A1 (pt)
CL (2) CL2009001170A1 (pt)
CO (1) CO6300930A2 (pt)
CR (1) CR11789A (pt)
CY (3) CY1121350T1 (pt)
DK (5) DK2299984T3 (pt)
EC (1) ECSP10010665A (pt)
ES (5) ES2774226T3 (pt)
FI (1) FI3782612T3 (pt)
HR (5) HRP20190100T1 (pt)
HU (5) HUE042825T2 (pt)
IL (2) IL238087B (pt)
LT (5) LT3782611T (pt)
MX (2) MX2010012470A (pt)
MY (1) MY161593A (pt)
NI (1) NI201000193A (pt)
NZ (3) NZ589437A (pt)
PE (2) PE20091971A1 (pt)
PL (5) PL3692983T3 (pt)
PT (5) PT3782612T (pt)
RU (3) RU2476207C2 (pt)
SG (1) SG193206A1 (pt)
SI (5) SI3692983T1 (pt)
TW (3) TWI618538B (pt)
WO (1) WO2009139888A1 (pt)
ZA (1) ZA201008229B (pt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8404716B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US8404717B2 (en) * 2002-10-15 2013-03-26 Celgene Corporation Methods of treating myelodysplastic syndromes using lenalidomide
US11116782B2 (en) 2002-10-15 2021-09-14 Celgene Corporation Methods of treating myelodysplastic syndromes with a combination therapy using lenalidomide and azacitidine
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) * 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US8497292B2 (en) * 2005-12-28 2013-07-30 Translational Therapeutics, Inc. Translational dysfunction based therapeutics
CA2742252A1 (en) * 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
US20150290228A1 (en) * 2008-05-15 2015-10-15 Jay T. BACKSTROM Oral formulations of cytidine analogs and methods of use thereof
AU2009246926B2 (en) 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2010093435A1 (en) * 2009-02-10 2010-08-19 Celgene International Sarl Methods for treating non-small cell lung cancer using 5-azacytidine
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
US20110301102A1 (en) * 2010-06-07 2011-12-08 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
US8759303B2 (en) 2010-06-07 2014-06-24 Telik, Inc. Compositions and methods for treating myelodysplastic syndrome
MY166014A (en) * 2010-06-07 2018-05-21 Abraxis Bioscience Llc Combination therapy methods for treating proliferative diseases
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
EP2481813A1 (en) * 2011-02-01 2012-08-01 Centro di Riferimento Oncologico - Istituto Nazionale Tumori - Aviano Markers of cutaneous melanoma and uses thereof
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法
MY176125A (en) 2011-11-03 2020-07-24 Takeda Pharmaceuticals Co Administration of nedd8-activating enzyme inhibitor and hypomethylating agent
US9474779B2 (en) 2012-01-19 2016-10-25 Agios Pharmaceuticals, Inc. Therapeutically active compositions and their methods of use
MX2015000804A (es) * 2012-07-20 2016-03-11 Star Biotechnology Llc Composiciones y metodos para tratar el sarcoma de ewing y otros trastornos relacionados con ews-fli1.
JP6444883B2 (ja) * 2012-11-29 2018-12-26 タカラ バイオ ヨーロッパ アーベー 哺乳類多能性幹細胞由来の内胚葉細胞を産生するための改良された方法
US20150031627A1 (en) 2013-07-25 2015-01-29 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
EA036325B1 (ru) 2014-03-14 2020-10-27 Аджиос Фармасьютикалз, Инк. Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
WO2015195634A1 (en) 2014-06-17 2015-12-23 Celgne Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
EP3925609B1 (en) 2014-08-22 2025-07-30 Celgene Corporation Methods of treating multiple myeloma with immunomodulatory compounds in combination with antibodies
JP2018515566A (ja) * 2015-05-22 2018-06-14 ノバルティス アーゲー 医薬組成物
UA123401C2 (uk) 2015-10-15 2021-03-31 Аджиос Фармасьютікалз, Інк. Комбінована терапія для лікування злоякісних пухлин
CA3002029A1 (en) * 2015-10-15 2017-04-20 Celgene Corporation Combination therapy for treating malignancies
ES2897959T3 (es) * 2015-10-15 2022-03-03 Servier Lab Terapia de combinación para tratar neoplasias malignas
DK3960182T3 (da) 2015-12-03 2025-04-07 Epidestiny Inc Sammensætninger indeholdende decitabin, 5-azacytidin og tetrahydrouridin samt anvendelser deraf
US11035850B2 (en) 2016-04-12 2021-06-15 The Johns Hopkins University Quantitative determination of nucleoside analogue drugs in genomic DNA or RNA
US10980788B2 (en) 2018-06-08 2021-04-20 Agios Pharmaceuticals, Inc. Therapy for treating malignancies
EA039874B1 (ru) * 2019-06-06 2022-03-22 Общество С Ограниченной Ответственностью "Технология Лекарств" Композиция помалидомида для лечения заболеваний, ассоциированных с фактором некроза опухоли (фно)
BR112021025537A2 (pt) 2019-06-20 2022-03-03 Celgene Quanticel Res Inc Azacitidina em combinação com venetoclax, gilteritinibe, midostaurina ou outros compostos para o tratamento de leucemia ou síndrome mielodisplásica
JP7680762B2 (ja) * 2019-09-25 2025-05-21 アードバーク・セラピューティクス・インコーポレイテッド 経口速放出性医薬組成物および減量治療の方法
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
MX2022004766A (es) 2019-10-21 2022-05-16 Novartis Ag Terapias combinadas con venetoclax e inhibidores de tim-3.
JP7653712B2 (ja) * 2019-12-18 2025-03-31 一般社団法人東京血液疾患研究所 高リスク骨髄異形成症候群の治療薬
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
EP4085902B1 (en) * 2019-12-31 2025-04-30 Jiangsu Yahong Meditech Co., Ltd. Pharmaceutical composition containing nitroxoline, nitroxoline tablet, preparation method therefor and use thereof
BR112022012310A2 (pt) 2020-01-17 2022-09-06 Novartis Ag Combinação compreendendo um inibidor de tim-3 e um agente hipometilante para uso no tratamento de síndrome mielodisplásica ou leucemia mielomonocítica crônica
CN115768432A (zh) 2020-04-23 2023-03-07 南方研究院 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
CA3186696A1 (en) 2020-07-23 2022-01-27 Mark J. Suto Polymorphs of 5-aza-4'-thio-2-deoxycytidine
AU2021386422A1 (en) * 2020-11-27 2023-07-06 Centre Leon Berard Ribosomal rnas 2'o-methylation as a novel source of biomarkers relevant for diagnosis, prognosis and therapy of cancers
US11858956B2 (en) 2020-12-18 2024-01-02 Southern Research Institute 6-aza-nucleoside prodrugs as antiviral agents for treating virus infections
WO2022192621A1 (en) 2021-03-12 2022-09-15 Celgene Corporation Methods for using a hypomethylating agent to treat diseases and disorders based on gene mutation profiles
AU2022370354A1 (en) 2021-10-19 2024-05-30 Akirabio, Inc. Compositions comprising 2'-deoxycytidine analogs and use thereof for the treatment of sickle cell disease, thalassemia, and cancers
US20250195653A1 (en) 2023-11-28 2025-06-19 Sanofi Multifunctional natural killer (nk) cell engager combination therapy for treating hematological neoplastic disorders
CN118903036B (zh) * 2024-10-10 2025-03-04 华夏罕见病药物研发(山东)有限公司 一种含尿苷的组合物的制备方法及其在治疗发育性癫痫性脑病50型中的应用

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2913408A (en) 1956-12-28 1959-11-17 Dow Chemical Co Corrosion inhibitors for ferrous metals in aqueous solutions of non-oxidizing acids
GB1050899A (pt) 1963-12-22
CH527207A (de) 1968-05-08 1972-08-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
CH507969A (de) 1968-11-12 1971-05-31 Ceskoslovenska Akademie Ved Verfahren zur Herstellung von 1-Glycosyl-5-azacytosinen
DE2012888C3 (de) 1970-03-14 1981-04-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 5-Azapyrimidinnucleosiden
FR2123632A6 (en) 1971-01-26 1972-09-15 Ceskoslovenska Akademie Ved Prepn of 5-azacytosines and 5-azacytidines - from bis trimethylsilyl-5-azacytosine
DE2122991C2 (de) 1971-05-04 1982-06-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von Cytosin- und 6-Azacytosinnucleosiden
DE2508312A1 (de) 1975-02-24 1976-09-02 Schering Ag Neues verfahren zur herstellung von nucleosiden
DE2757365A1 (de) 1977-12-20 1979-06-21 Schering Ag Neues verfahren zur herstellung von nucleosiden
JPS59151784U (ja) 1983-03-30 1984-10-11 日産自動車株式会社 トラツクのリヤボデイ構造
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
JPS63500636A (ja) 1985-08-23 1988-03-10 麒麟麦酒株式会社 多分化能性顆粒球コロニー刺激因子をコードするｄｎａ
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
EP0397042B1 (de) 1989-05-10 1995-08-16 F. Hoffmann-La Roche Ag Herstellung von Isochinolinderivaten
US5360352A (en) 1992-12-24 1994-11-01 The Whitaker Corporation Wire retainer for current mode coupler
US6432924B1 (en) 1993-12-26 2002-08-13 East Carolina University Method of treating disorders characterized by overexpression of cytidine deaminase or deoxycytidine deaminase
GB9412394D0 (en) 1994-06-21 1994-08-10 Danbiosyst Uk Colonic drug delivery composition
US5700640A (en) 1994-09-16 1997-12-23 Basf Aktiengesellschaft Inducers of gamma globin gene expression and screening assays therefor
US5539209A (en) 1994-10-17 1996-07-23 Trojan Technologies Inc. Method of cleaning fouling materials from a radiation module
AU738170B2 (en) 1996-10-16 2001-09-13 Icn Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
US6635280B2 (en) 1997-06-06 2003-10-21 Depomed, Inc. Extending the duration of drug release within the stomach during the fed mode
PT998271E (pt) 1997-06-06 2005-10-31 Depomed Inc Formas de dosagem oral de farmacos com retencao gastrica para a libertacao controlada de farmacos altamente soluveis
US6200604B1 (en) 1998-03-27 2001-03-13 Cima Labs Inc. Sublingual buccal effervescent
US6566395B1 (en) 1999-05-25 2003-05-20 Biomedicines, Inc. Methods of treating proliferative disorders
US6803195B1 (en) 1999-07-02 2004-10-12 Ramot At Tel-Aviv University Ltd. Facile detection of cancer and cancer risk based on level of coordination between alleles
KR20020012006A (ko) 1999-07-16 2002-02-09 오오쯔끼쥰조 점막 흡수용 글리시리진 제제
US20030180352A1 (en) 1999-11-23 2003-09-25 Patel Mahesh V. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
PT1251832E (pt) 2000-02-04 2007-01-31 Depomed Inc Forma de dosagem constituída por invólucro-e-núcleo que conduz a uma libertação do fármaco de ordem zero
GB0102342D0 (en) 2001-01-30 2001-03-14 Smithkline Beecham Plc Pharmaceutical formulation
WO2002098420A1 (en) 2001-06-01 2002-12-12 Cytovia, Inc. 4-substituted-1-(arylmethylidene)thiosemicarbazide, 4-substituted-1-(arylcarbonyl)thiosemicarbazide and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6723340B2 (en) 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US20030220254A1 (en) 2002-03-29 2003-11-27 Texas Tech University System Composition and method for preparation of an oral dual controlled release formulation of a protein and inhibitor
US7772197B2 (en) 2002-09-24 2010-08-10 1,3,5-Triazines for Treatment of Viral Diseases 1,3,5-triazines for treatment of viral diseases
US7189740B2 (en) 2002-10-15 2007-03-13 Celgene Corporation Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes
EP1556010A4 (en) 2002-10-31 2007-12-05 Supergen Inc PHARMACEUTICAL FORMULATIONS; WHICH ARE ADDRESSED TO CERTAIN REGIONS OF THE STOMACH-DARM TRAKTS
EP1581213A4 (en) 2002-12-18 2008-11-19 Cytovia Inc 3,5-DISUBSTITUTED 1,2,4-OXADIAZOLE AND ANALOGUE TO ACTIVATE CASPASE AND INTRODUCTION OF APOPTOSIS AND THEIR USE
US6887855B2 (en) 2003-03-17 2005-05-03 Pharmion Corporation Forms of 5-azacytidine
US6943249B2 (en) 2003-03-17 2005-09-13 Ash Stevens, Inc. Methods for isolating crystalline Form I of 5-azacytidine
US7038038B2 (en) 2003-03-17 2006-05-02 Pharmion Corporation Synthesis of 5-azacytidine
AU2004241729A1 (en) 2003-05-21 2004-12-02 Novartis Ag Combination of histone deacetylase inhibitors with chemotherapeutic agents
JP2007504131A (ja) * 2003-08-29 2007-03-01 エートン ファーマ インコーポレーティッド 癌の組み合わせ処置法
US7192781B2 (en) 2004-04-13 2007-03-20 Pharmion Corporation Methods for stabilizing 5-azacytidine in plasma
US20060069060A1 (en) 2004-09-27 2006-03-30 Sanjeev Redkar Salts of decitabine
US20060063735A1 (en) 2004-09-17 2006-03-23 Supergen, Inc. Salts of 5-azacytidine
CN100374160C (zh) * 2004-11-22 2008-03-12 山东蓝金生物工程有限公司 一种含抗代谢类药物的抗癌药物组合物
US20060128654A1 (en) 2004-12-10 2006-06-15 Chunlin Tang Pharmaceutical formulation of cytidine analogs and derivatives
CA2598239C (en) 2005-02-18 2019-10-29 Abraxis Bioscience, Inc. Nanoparticulate formulations of taxanes and carrier proteins for use in combination chemotherapy
NZ561178A (en) 2005-03-07 2010-11-26 Bayer Schering Pharma Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
CN100500212C (zh) * 2005-04-06 2009-06-17 山东蓝金生物工程有限公司 一种抗实体肿瘤药物组合物
US8058260B2 (en) 2006-05-22 2011-11-15 Xenoport, Inc. 2′-C-methyl-ribofuranosyl cytidine prodrugs, pharmaceutical compositions and uses thereof
WO2008028193A2 (en) 2006-09-01 2008-03-06 Pharmion Corporation Colon-targeted oral formulations of cytidine analogs
US7759481B2 (en) 2007-01-11 2010-07-20 Ivax Corporation Solid state forms of 5-azacytidine and processes for preparation thereof
WO2008092127A1 (en) 2007-01-25 2008-07-31 Nevada Cancer Institute Use of acetylated or esterificated azacytidine, decitabine, or other nucleoside analogs as oral agents for the treatment of tumors or other dysplastic syndromes sensitive to hypomethylating agents
JP5173298B2 (ja) 2007-07-25 2013-04-03 キヤノン株式会社 プリント配線板およびそれを用いた電子機器
EP2176279A4 (en) 2007-08-02 2012-01-11 Chemagis Ltd HIGH-PURITY, STABLE AZACYTIDINE AND METHODS OF PREPARATION
US8399420B2 (en) 2007-09-26 2013-03-19 Mount Sanai School of Medicine Azacytidine analogues and uses thereof
EP2048151A1 (en) 2007-10-10 2009-04-15 Cilag AG Method for producing nucleosides by direct glycosylation of the nucleoside base
JO2778B1 (en) 2007-10-16 2014-03-15 ايساي انك Certain Compounds, Compositions and Methods
CA2742252A1 (en) 2007-11-01 2009-05-07 Celgene Corporation Cytidine analogs for treatment of myelodysplastic syndromes
AU2009246926B2 (en) * 2008-05-15 2014-06-26 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
EP2321302B1 (en) 2008-08-01 2014-10-29 Dr. Reddy's Laboratories Ltd. Azacitidine process and polymorphs
WO2010017374A1 (en) 2008-08-06 2010-02-11 Sicor Inc. Process for preparing azacytidine intermediate
KR101660549B1 (ko) 2008-08-08 2016-09-27 시노팜 타이완 리미티드 ５―아자시토신 뉴클레오시드 및 이의 유도체의 제조 방법
KR20170015525A (ko) 2008-11-22 2017-02-08 제넨테크, 인크. 유방암의 치료를 위한, 화학요법과 조합된 항-ｖｅｇｆ 항체의 용도
US20110042247A1 (en) 2009-06-25 2011-02-24 Chandrasekhar Kocherlakota Formulations of azacitidine and its derivatives
WO2011014541A1 (en) 2009-07-30 2011-02-03 Eagle Pharmaceuticals, Inc. Stable formulations of azacitidine
IT1399195B1 (it) 2010-03-30 2013-04-11 Chemi Spa Processo per la sintesi di azacitidina e decitabina
CN103338753A (zh) 2011-01-31 2013-10-02 细胞基因公司 胞苷类似物的药物组合物及其使用方法
JP6289361B2 (ja) 2011-03-31 2018-03-07 セルジーン インターナショナル サルル ５−アザシチジンの合成
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
HK1200716A1 (zh) 2011-11-01 2015-08-14 细胞基因公司 使用胞苷類似物的口服製劑治療癌症的方法

Also Published As

Publication number Publication date
HRP20200096T1 (hr) 2020-04-03
CY1124720T1 (el) 2022-07-22
LT2695609T (lt) 2020-02-10
US20230241086A1 (en) 2023-08-03
JP2017137326A (ja) 2017-08-10
PT2695609T (pt) 2020-03-02
US20180153916A1 (en) 2018-06-07
PL3782611T3 (pl) 2022-11-07
PT3782612T (pt) 2024-01-18
AU2013202665B2 (en) 2015-06-25
EP3692983B1 (en) 2021-08-11
FI3782612T3 (fi) 2024-01-16
BRPI0912717A2 (pt) 2014-12-23
EP3782612A1 (en) 2021-02-24
DK2695609T3 (da) 2020-02-10
NZ602833A (en) 2014-04-30
RU2012147739A (ru) 2014-05-20
US20230255996A1 (en) 2023-08-17
HUE047707T2 (hu) 2020-05-28
EP3782611A1 (en) 2021-02-24
SI2299984T1 (sl) 2019-04-30
HRP20190100T1 (hr) 2019-04-05
LT3782612T (lt) 2023-12-27
US20150056280A1 (en) 2015-02-26
US20220079964A1 (en) 2022-03-17
JP2015110575A (ja) 2015-06-18
AU2015202884A1 (en) 2015-06-18
CL2013001097A1 (es) 2013-11-29
IL238087B (en) 2019-01-31
CY1122681T1 (el) 2020-10-14
EP3782612B1 (en) 2023-11-08
CA2761582C (en) 2022-06-07
US12053482B2 (en) 2024-08-06
JP6426778B2 (ja) 2018-11-21
TWI618538B (zh) 2018-03-21
HUE064677T2 (hu) 2024-04-28
ECSP10010665A (es) 2011-01-31
ES2774226T3 (es) 2020-07-17
EP2299984A1 (en) 2011-03-30
TW201006478A (en) 2010-02-16
DK2299984T3 (en) 2019-03-04
US20200101095A1 (en) 2020-04-02
CO6300930A2 (es) 2011-07-21
SI3692983T1 (sl) 2021-11-30
PT3782611T (pt) 2022-11-18
RU2476207C2 (ru) 2013-02-27
AU2009246926A1 (en) 2009-11-19
US20200316099A1 (en) 2020-10-08
US10646503B2 (en) 2020-05-12
NZ589437A (en) 2012-11-30
ES2969144T3 (es) 2024-05-16
EP3782611B1 (en) 2022-07-06
US10463683B2 (en) 2019-11-05
LT3782611T (lt) 2022-10-10
PE20091971A1 (es) 2010-01-15
US20190231803A1 (en) 2019-08-01
ES2712506T3 (es) 2019-05-13
PT2299984T (pt) 2019-02-25
TW201729817A (zh) 2017-09-01
CL2009001170A1 (es) 2010-06-04
TW201513869A (zh) 2015-04-16
EP2695609B1 (en) 2019-12-11
LT2299984T (lt) 2019-03-25
KR101633134B1 (ko) 2016-06-23
PL3692983T3 (pl) 2021-12-27
CN102099018B (zh) 2016-01-13
AU2009246926B2 (en) 2014-06-26
NI201000193A (es) 2011-08-01
EP3692983A1 (en) 2020-08-12
US20150374732A1 (en) 2015-12-31
RU2018109222A3 (pt) 2021-07-02
SI3782611T1 (sl) 2022-10-28
US10220050B2 (en) 2019-03-05
HUE042825T2 (hu) 2019-07-29
CA3094580A1 (en) 2009-11-19
RU2018109222A (ru) 2019-09-17
LT3692983T (lt) 2021-11-10
NZ623495A (en) 2015-08-28
US20090286752A1 (en) 2009-11-19
IL209307A0 (en) 2011-01-31
MX2010012470A (es) 2010-12-02
HRP20231439T1 (hr) 2024-03-01
ES2893785T3 (es) 2022-02-10
EP2695609A1 (en) 2014-02-12
MY161593A (en) 2017-04-28
AR071808A1 (es) 2010-07-14
US11571436B2 (en) 2023-02-07
WO2009139888A1 (en) 2009-11-19
DK3782611T3 (da) 2022-09-05
PE20142440A1 (es) 2015-01-28
CN105535008A (zh) 2016-05-04
AU2015202884B2 (en) 2017-02-23
HUE059635T2 (hu) 2022-12-28
HUE055911T2 (hu) 2021-12-28
SI3782612T1 (sl) 2024-02-29
CA2761582A1 (en) 2009-11-19
EP2299984B1 (en) 2018-11-28
EP4327888A3 (en) 2024-05-22
PL2299984T3 (pl) 2019-07-31
ES2927556T3 (es) 2022-11-08
HRP20211398T1 (hr) 2021-12-10
MX363023B (es) 2019-03-05
HRP20221064T1 (hr) 2022-11-11
TWI522103B (zh) 2016-02-21
AU2013202665A1 (en) 2013-05-02
US20250082661A1 (en) 2025-03-13
IL209307A (en) 2016-02-29
CY1121350T1 (el) 2020-05-29
PL2695609T3 (pl) 2020-05-18
US8846628B2 (en) 2014-09-30
CN103479586B (zh) 2017-03-01
US20220105118A1 (en) 2022-04-07
DK3782612T3 (da) 2024-01-15
PL3782612T3 (pl) 2024-03-04
SG193206A1 (en) 2013-09-30
DK3692983T3 (da) 2021-09-20
SI2695609T1 (sl) 2020-03-31
JP2011520880A (ja) 2011-07-21
CN103479586A (zh) 2014-01-01
EP4327888A2 (en) 2024-02-28
CN102099018A (zh) 2011-06-15
JP6105547B2 (ja) 2017-03-29
CR11789A (es) 2011-02-21
ZA201008229B (en) 2012-02-29
CA3094580C (en) 2021-05-18
CA3094590A1 (en) 2009-11-19
RU2010151428A (ru) 2012-06-20
KR20110015629A (ko) 2011-02-16
RU2765076C2 (ru) 2022-01-25

Similar Documents

Publication Publication Date Title
IL209307A0 (en) Oral formulations of cytidine analogs and methods of use thereof
IL255813A (en) Compositions of 5-fluorocytosine and their uses
GB0915693D0 (en) Fatty acid formulations and methods of use thereof
ZA201008090B (en) Methods and compositions for oral administration of exenatide
PL2173345T3 (pl) Doustna formulacja metadoksyny
ZA200905741B (en) Indenoisoquinolinone analogs and methods of use thereof
PL2285450T3 (pl) Kompozycje do higieny jamy ustnej i sposoby
IL213559A0 (en) Oral formulations
ZA201100944B (en) Oral formulations of chemotherapeutic agents
EP2274325A4 (en) ANALOGUE OF HUMAN G-CSF AND METHOD OF MANUFACTURE AND APPLICATION THEREOF
IL210956A0 (en) Methionine analogs and methods of using same
TWM388323U (en) Improved structure of dental handpiece (1)
IL208967A0 (en) Methods and compositions for oral administration of exenatide
IL208165A0 (en) Methods and compositions for oral administration of proteins